General Information of Drug (ID: DMNBLQ8)

Drug Name
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline Drug Info
Synonyms CHEMBL98798; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44331231
TTD Drug ID
DMNBLQ8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [2]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [3]
Becaplermin DM1R5X4 Diabetic complication 5A2Y Approved [4]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [5]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [8]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [9]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [12]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [13]
Gefitinib DM15F0X Colon adenocarcinoma Approved [14]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [15]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [16]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [17]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [18]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [19]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [17]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [1]

References

1 A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
2 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
3 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
6 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
7 National Cancer Institute Drug Dictionary (drug id 452042).
8 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
9 Company report (Neuronova)
10 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
11 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
12 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
13 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
14 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
15 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
16 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
18 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
19 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
20 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).